SuperworthTScan Therapeutics price to sales ratio TCRX
Market value divided by revenue over the last twelve months, since 2022.
- Today, Oct 23, 2026
- 1.9×
- 5-year median
- 7.6×
- Against its 5-year history
- 5th
- percentile: 0 is its lowest day, 100 its highest
- 5-year range
- 1.2× to 39.8×
- Peer median
- 1.1×
TScan Therapeutics' price to sales ratio is 1.9× as of Oct 23, 2026.
That is below its 5-year median of 7.6×, lower than on 95% of days in the last 5 years.
Over that time it ranged from 1.2× in May 2022 to 39.8× in Mar 2025.
The median for 7 healthcare stocks of a similar size is 1.1×.
Price to sales ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2026 so far | 1.9× | 1.9× | 9.0× |
| 2025 | 7.1× | 6.0× | 39.8× |
| 2024 | 17.4× | 14.2× | 32.0× |
| 2023 | 16.5× | 3.0× | 18.5× |
| 2022 | 2.8× | 1.2× | 9.5× |
Against its peers
Companies in Healthcare nearest TScan Therapeutics' size, closest first, today.
| Company | Price to sales ratio |
|---|---|
| TCRXTScan Therapeutics | 1.9× |
| NEPHNephros | 1.9× |
| ATNMActinium Pharmaceuticals | n/m |
| APTAlpha Pro Tech | 0.9× |
| SPROSpero Therapeutics | 1.4× |
| LFVNLifevantage | 0.4× |
| ICCCImmucell | 3.0× |
| KEQUKewaunee Scientific | 0.3× |
| Peer median | 1.1× |
Where TScan Therapeutics ranks
What the price to sales ratio tells you
Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.
Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.
More on TScan Therapeutics
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.